Bionano Genomics Inc
NASDAQ:BNGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bionano Genomics Inc
Operating Income
Bionano Genomics Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bionano Genomics Inc
NASDAQ:BNGO
|
Operating Income
-$33.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Operating Income
$8.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
12%
|
|
|
Danaher Corp
NYSE:DHR
|
Operating Income
$5.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Waters Corp
NYSE:WAT
|
Operating Income
$800.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Operating Income
$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Operating Income
$2.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
Bionano Genomics Inc
Glance View
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The company is headquartered in San Diego, California and currently employs 299 full-time employees. The company went IPO on 2018-08-01. The firm offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. The company markets and sell the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.
See Also
What is Bionano Genomics Inc's Operating Income?
Operating Income
-33.3m
USD
Based on the financial report for Dec 31, 2025, Bionano Genomics Inc's Operating Income amounts to -33.3m USD.
What is Bionano Genomics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
2%
Over the last year, the Operating Income growth was 56%. The average annual Operating Income growth rates for Bionano Genomics Inc have been 36% over the past three years , 2% over the past five years .
